News Charles River Laboratories International, Inc. Xetra

Stocks

RV6

US1598641074

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 03:21:20 31/07/2026 pm IST			5-day change	1st Jan Change
204.85 ^EUR	-5.10%		-10.60%	-

30/07	Align Technology to add directors, launch review after deal with Elliott	RE
20/07	Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix…

All News

Mentions Relevance

15/07	Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call	BU
13/07	BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220	MT
13/07	Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating	MT
13/07	Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics	MT
13/07	Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	CI
13/07	Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating	MT
13/07	Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	BU
09/07	Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT
07/07	Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT
03/07	Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders?	PR
02/07	Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing	MT
01/07	Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating	MT
18/06	Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise	BU
18/06	Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating	MT
18/06	Charles River Laboratories Shares Rise After Morgan Stanley Upgrade	MT
17/06	Morgan Stanley Upgrades Charles River Laboratories International to Overweight From Equal Weight, Adjusts PT to $220 From $185	MT
05/06	Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says	MT
03/06	Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 09:55 AM
03/06	Charles River Laboratories International, Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 10:00 AM
01/06	Charles River Laboratories to Present at William Blair and Jefferies Conferences	BU
13/05	Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing	MT
13/05	Charles River Laboratories and Medipost sign non-exclusive MoU to advance GMP testing solutions	RE
13/05	Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions	BU
12/05	Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors	CI
12/05	Charles River Laboratories International, Inc. Announces Board Elections	CI